Journal
CURRENT UROLOGY REPORTS
Volume 13, Issue 1, Pages 16-23Publisher
SPRINGER
DOI: 10.1007/s11934-011-0232-y
Keywords
Targeted therapy; Sunitinib; Sorafenib; Everolimus; Temsirolimus; Pazopanib; Axitinib; Nephrectomy; Renal cell cancer; Kidneys
Categories
Funding
- Roche
- Pfizer
Ask authors/readers for more resources
During the past half-decade, clinical trials have permitted major progress in treatment of metastatic renal cell carcinoma with the first generation of targeted therapies (bevacizumab, sunitinib, sorafenib, everolimus, and temsirolimus). New targeted agents such as axitinib, tivozanib, and dovitinib, all of which are tyrosine kinase inhibitors, have been developed in treatment of metastatic renal cell carcinoma. In the same time, more information regarding mechanism of disease and drug resistance shed light on new targets and new potent agents. We report an overview of the more relevant data published over the past year, which may modify the therapeutic landscape of kidney cancer in the near future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available